





Preserving capsular shape and endocapsular space



eyepcr.com
info@eyepcr.com



THE CLINICAL CHALLENGE

The capsular environment matters

Capsular bag deformation and fibrosis following replacement of the natural crystalline lens with an intraocular lens (IOL) implant may contribute to:

POSTOPERATIVE COMPLICATIONS

- Posterior capsule opacification
- IOL instability
- Dysphotopsia
- Posterior vitreous detachment
- Refractive surprises

AND

COMPLEXITY IN FUTURE IOL EXCHANGE

- Fibrosis around the IOL haptics
- Increased risk of tearing the zonules
- Increased risk of damaging the corneal endothelial cells


Up to 30–40% of patients are affected 3–5 years after surgery.*

* For a list of peer-reviewed references visit our website: eyepcr.com/resources

THE SOLUTION

fixOflex: a new paradigm in capsular management

From reactive complication management to proactive capsular care, fixOflex is designed to preserve capsular shape and endocapsular space/volume following phacoemulsification.



Anticipated Benefits

01

Prevention of cell migration

02

Stabilization of IOL optics

03

Reduction of dysphotopsia

04

Ease of IOL exchange

05

Reduction of vitreous movement

Evidence varies by claim: clinically demonstrated, bench or case(s) report - supported, or requiring further studies^{1 2 3 4}

Main clinical trial results at 12 months¹


Objective: to evaluate the safety and efficacy of a novel endocapsular device used during cataract surgery.

Study design

- **Cohort study**, university-affiliated private practice; one eye per patient
- **Adults with age-related cataract**, IOL 14–26 D, no other ocular pathology
- **Endpoints:** safety – adverse events (AEs); efficacy – PCO at 12 months vs retrospective control
- **IOL power calculation** using the Haigis formula, 2.4-mm injector




PCO at 12 months
vs 13% control



Nd:YAG capsulotomy
vs 6.5% control





Mean device
implantation time



AEs, all resolved and deemed
unrelated to the device


BEYOND THE CLINICAL STUDY

Optical bench and model-eye evidence^{2,3}



IOL only

light leaking
around IOL



IOL in fixOflex

dysphotopsia
blocked

In vitro optical quality of IOLs implanted in the fixOflex device: 5 monofocal and 5 trifocal IOLs, tested before and after implantation.

< 0.03 mm decentration along the clip axis

P > 0.1 MTF, no significant change

+0.10 log(s) straylight at 5.5 mm, below clinical thresholds

Negative dysphotopsia and other entoptic phenomena compared between a standard IOL alone and the same IOL in fixOflex, with a glare source at 0–60°.


~75° shadow, IOL alone (stronger at 3 mm)

None shadow with fixOflex, any pupil

None positive dysphotopsia, any condition

fixOflex at a glance

Indicated for implantation in combination with an IOL during replacement of the crystalline lens by an IOL implant.



EYE PCR

Westerdoksdiik 423 · 1013 BX Amsterdam
The Netherlands
info@eyepcr.com · +31 20 237 7777
+30 2811 392101



Scientific publications, IOL &
injector list
eyepcr.com/resources

Material	Hydrophilic acrylic, pre-polymerized (Contamac CI26Y)
Overall diameter	9.80 mm
Overall thickness	1.8 mm
Weight	32.5 mg
Central opening	Approx. 6 mm, accepts IOLs with a 6-mm optic
IOL retention	Two inner retention clips · four peripheral holes
Regulatory	Class IIb implantable · CE 2803 · Regulation (EU) 2017/745
Sterilisation / supply	Steam · sterile glass vial in purified water, sealed peel pouch
Storage / use	15 °C to 35 °C, protected from moisture and light · single use
Implantation	In the capsular bag before the IOL · incision as small as 2.2 mm
Injector	Soft tip · implant within 15 min of loading
Qualified IOLs & injectors	eyepcr.com/qualified

References

- [1] Pallikaris IG, Elmassry A, et al. Transl Vis Sci Technol. 2026;15(2):8. Figure: CC BY 4.0.
- [2] Britz L, Hammer M, Łabuz G, et al. Transl Vis Sci Technol. 2026;15(7):5.
- [3] Pallikaris IG, Tsoukalas S, et al. Invest Ophthalmol Vis Sci. 2025;66(8):2233 (ARVO 2025, A0413).
- [4] Noguchi S, Pallikaris I. Breakthrough with Artificial Capsular Bag in Cataract Surgery. Film 97406, 2024 ASCRS Annual Meeting (Grand Prize, ASCRS Film Festival).

For professional use only. Refer to the Instructions for Use for complete indications, contraindications, warnings and instructions. Product render (F1), not to scale.